Drugs / YG1699
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06648876 | Oct 2024 → Aug 2025 overdue | chronic kidney disease, diabetes mellitus | RenJi Hospital | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05089617 | Jan → Aug 2022 | diabetes mellitus | Youngene Therapeutics Inc., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03953092 | May → Nov 2019 | diabetes mellitus | Youngene Therapeutics Inc., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04956263 | Jun 2021 → Feb 2022 | type 1 diabetes mellitus | Youngene Therapeutics Inc., Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YG1699 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03953092 ↗ |
| Action | Inhibit | “YG1699 is a novel investigational dual inhibitor of sodium-dependent glucose cotransporters, SGLT1 and SGLT2” NCT04956263 ↗ |
| Modality | Small molecule | “belonging to c-aryl glucoside derivatives” NCT06648876 ↗ |
| Route | Oral | “following single and multiple ascending oral dose administration” NCT03953092 ↗ |